- $568.14m
- $595.14m
- $687.80m
- 69
- 75
- 49
- 70
Annual income statement for Avanos Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 715 | 745 | 684 | 673 | 688 |
| Cost of Revenue | |||||
| Gross Profit | 373 | 364 | 394 | 380 | 381 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 761 | 736 | 650 | 669 | 1,084 |
| Operating Profit | -46.1 | 8.9 | 34.4 | 4.2 | -396 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -60.5 | 5.8 | 26.7 | -7.9 | -403 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -27.2 | 5.2 | 21.5 | -9.9 | -386 |
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -27.2 | 5.2 | 50.5 | -61.8 | -392 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -27.2 | 5.2 | 50.5 | -61.8 | -392 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 0.69 | 1.05 | 0.713 | 0.502 | -1.92 |